Vivani Medical (NASDAQ:VANI) Director Gregg Williams Purchases 1,587,301 Shares

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,587,301 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the acquisition, the director owned 36,119,086 shares in the company, valued at approximately $45,510,048.36. The trade was a 4.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Gregg Williams also recently made the following trade(s):

• On Friday, May 15th, Gregg Williams bought 1,587,301 shares of Vivani Medical stock. The shares were acquired at an average price of $1.26 per share, for a total transaction of $1,999,999.26.
• On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were acquired at an average price of $1.26 per share, for a total transaction of $1,999,999.26.

Vivani Medical Stock Performance

Shares of VANI stock opened at $1.13 on Tuesday. Vivani Medical, Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $1.92. The firm has a market capitalization of $97.45 million, a price-to-earnings ratio of -2.82 and a beta of 2.31. The stock’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $1.26.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). As a group, equities analysts forecast that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

VANI has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Tuesday, June 9th. HC Wainwright lowered their price target on Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.50.

Institutional Trading of Vivani Medical

Institutional investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical during the 4th quarter worth approximately $1,127,000. Geode Capital Management LLC boosted its stake in shares of Vivani Medical by 29.6% in the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after acquiring an additional 105,398 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Vivani Medical during the fourth quarter worth approximately $174,000. State Street Corp raised its stake in Vivani Medical by 12.5% in the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after purchasing an additional 16,070 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Vivani Medical in the 4th quarter valued at $60,000. Institutional investors and hedge funds own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.